ASX Announcements

Archive
5 September 2022

Notification of cessation of securities - LCT

Living Cell Technologies provides notification of the cessation of options expiring on various dates at various prices.

31 August 2022

Preliminary Final Report and 2022 Financial Statements

Living Cell Technologies has released its Preliminary Final Report (Appendix 4E) for the financial year ended 30 June 2022, highlighted by further advances in the Company’s third clinical trial of NTCELL in Parkinson’s disease.

15 August 2022

Choroid plexus tissue shipped to Sydney as NTCELL research advances

Living Cell Technologies has advanced its Parkinson’s disease research, with choroid plexus tissue successfully shipped from New Zealand to Australia as part of the third clinical trial of NTCELL. 

29 July 2022

Quarterly Activity Report and Appendix 4C

LCT's Activity and Cashflow (Appendix 4C) report for the June quarter 2022, highlighted by the move to apply the benefits of artificial intelligence towards the Company’s third clinical trial of NTCELL in Parkinson’s disease. 

28 July 2022

Change of Director's Interest Notice - B Tuch and A Kelly

Change of Director's Interest Notice for LCT Directors, Professor Bernie Tuch and Dr Andrew Kelly.